Genentech says VOYAGER real-world study supports Vabysmo effectiveness, safety across retinal diseases

Genentech presented 12-month and 6-month VOYAGER real-world results at EURETINA 2026, reporting sustained vision outcomes and broad anatomical improvements across wet AMD, diabetic macular edema and retinal vein occlusion. The study enrolled more than 5,000 patients and reported no new safety signals.